Summit Therapeutics Inc. Net Change in Cash
Summit Therapeutics Inc. (SMMT) reported Net Change in Cash of $194.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-23
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$118.75M, a 211.34% decline year-over-year.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $106.66M.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$9.81M.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$577.64M, a 10307.42% decline year-over-year.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $120.39M, a 256.60% increase from fiscal 2024.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $33.76M.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$577.18M, a 200.06% decline from fiscal 2022.
- Summit Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $576.82M, a 10633.46% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $194.10M 10-Q · filed 2026-07-23 | ||||
| 2026-03-31 | -$118.75M 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | $120.39M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $133.69M 10-Q · filed 2025-10-20 | ||||
| 2025-06-30 | $193.00M 10-Q · filed 2026-07-23 | ||||
| 2025-03-31 | $106.66M 10-Q · filed 2026-04-30 | ||||
| 2024-12-31 | $33.76M 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | $22.67M 10-Q · filed 2025-10-20 | ||||
| 2024-06-30 | -$42.67M 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | -$9.81M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$577.18M 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$624.82M 10-Q · filed 2024-10-30 | ||||
| 2023-06-30 | -$606.49M 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | -$577.64M 10-Q · filed 2024-05-01 | ||||
| 2022-12-31 | $576.82M 10-K · filed 2025-02-24 | ||||
| 2022-09-30 | $50.18M 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | -$14.46M 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | $5.66M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $5.37M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $13.83M 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $36.97M 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | $35.78M 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | $2.58M 10-K/A · filed 2022-12-21 | ||||
| 2020-09-30 | -$42.57M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$27.43M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | -$8.90M 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $28.60M 10-K · filed 2021-03-31 | ||||
| 2019-01-31 | $6.75M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |